Becton, Dickinson and Company (NYSE:BDX) will begin trading ex-dividend on December 9, 2020. The quarterly dividend payment of $ 0.83 per share is scheduled to be paid on December 31, 2020. The dividend yield based on the latest trading day closing price was 1.40 percent. Shareholders who purchased BDX shares prior to the ex-dividend date are eligible for the cash dividend payment.
Dividends History
wpDataTable with provided ID not found!Click Here For More Historical Dividends Of Becton, Dickinson and Company
Becton, Dickinson and Company recently reported third quarter financial results on August 6, 2020, before market open, the Franklin Lakes based company recorded income for the third quarter of $ 2.20 per share, from the revenue of $ 3,855.00 million. The quarterly earnings contracted 28.57 percent while revenues decreased 11.38 percent compared with the same quarter last year.
Wall street analysts are predicting, BDX to report 3Q20 income of $ 2.04 per share from revenue of $ 3943.15 million. The bottom line results beat street analysts by $ 0.16 or 7.84 percent, at the same time, top line results fell short of analysts by $ 88.15 million or 2.24 percent.
Stock Performance
Shares of Becton, Dickinson and Company traded low $ -6.31 or -2.60 percent on Monday, reaching $ 236.45 with volume of 1.27 million shares. Becton, Dickinson and Company has traded high as $ 243.58 and has cracked $ 235.86 on the downward trend
According to the previous trading day, closing price of $ 236.45, representing a 22.76 % increase from the 52 week low of $ 197.75 and a 15.33 % decrease over the 52 week high of $ 286.72.
The company has a market capital of $ 68.58 billion and is part of the Healthcare sector and Medical Instruments & Supplies industry.
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The companys BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, monoclonal antibodies and kits, reagent systems, bench-side solutions, and molecular indexing and next-generation sequencing sample preparation products, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers.
